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Abstract
Background:  Artemisinin-derivative formulations are now widely used to treat falciparum
malaria. However, the dry powder suspensions developed for children are few and/or are of poor
quality. In addition to the active compound, the presence of a suitable preservative in these
medicines is essential. In this study, an evaluation of the preservative content and efficacy in some
dry suspensions available on the Kenyan market was performed.
Method: UV spectrophotometry was used to identify the preservatives in each sample while
HPLC-UV was used for quantification. After reconstitution of the powders in water, the dissolution
of the preservatives was followed for 7 days. Antimicrobial efficacy of the preservatives was
assessed by conducting a preservative efficacy test (PET) following the European pharmacopoeia
standards.
Results: Four different preservatives were identified namely methylparahydroxybenzoate (MP),
propylparahydroxybenzoate (PP), benzoic acid and sorbic acid. MP and PP were identified in
Artesiane® (artemether 300 mg/100 ml), Alaxin® (dihydroartemisinin 160 mg/80 ml) andGvither ®
(artemether 300 mg/100 ml) respectively. Sorbic acid was presentin Artenam® (artemether 180
mg/60 ml) while benzoic acid was identified in Santecxin® (dihydroartemisinin 160 mg/80 ml)
andArtexin® (dihydroartemisinin 160 mg/80 ml) respectively. Cotecxin® (dihydroartemisinin 160
mg/80 ml) did not contain any of the above preservatives. After reconstitution in water,
preservativesin 50%(3/6) of the products did not completely dissolve and the PET results revealed
that only Artenam® and Gvither® met the requirements for antimicrobial efficacy. The other
products did not conform.
Conclusion: These results show that paediatric antimalarial dry powder formulations on the
market may contain ineffective or incorrect amounts of preservatives. This is a potential risk to the
patient. Studies conducted on the dry powder suspensions should include the analysis of both the
active ingredient and the preservative, including the efficacy of the latter.
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Background
The artemisinin-derivatives, artemether, artesunate,
arteether and dihydroartemisinin, are currently the most
potent antimalarial medicines on the market. They are
widely available in the different pharmaceutical dosage
forms including tablets, injections, suppositories and dry
powders [1].
Since artemisinin and its derivatives are poorly water-sol-
uble and are not very stable in solution, the preparations
have to be formulated in the dry form for subsequent
reconstitution into a wet suspension with water just
before use. The dry powders for reconstitution are nor-
mally designed for children from 0–5 years of age, who
are not able to swallow tablets. In the malaria endemic
countries, living conditions are often poor, including
scarce access to clean portable drinking water [2]. As a
result, microorganisms can easily thrive when the dry
powder is reconstituted with poor quality water. In addi-
tion, children suffering from malaria, as well as AIDS or
typhoid, have a weakened immunological system and are,
therefore, more susceptible to other infections. Moreover,
the drugs are packaged in multiple dose containers, mak-
ing the preparation highly susceptible to contamination
following frequent use. Hence, pharmaceutical prepara-
tions which need an aqueous vehicle such as syrups and
powders for oral suspensions require safeguards from
microbial contamination, which may affect product sta-
bility or infect the consumer. This is accomplished by the
addition of antimicrobial agents in the formulation to
destroy and inhibit the growth of those organisms that
may contaminate the product during manufacture or use
[3].
The International Committee on Harmonization (ICH)
guidelines [4] requests that for submission of drug regis-
tration dossier on dry powders for oral suspensions, data
should be provided for the content of the active pharma-
ceutical ingredient (API) as well as the type(s) and
amount(s) of the preservative(s) used. In addition, the
efficacy of the antimicrobial preservation should be dem-
onstrated by challenging the reconstituted suspension in
its final container with specified microorganisms. This
implies that the preservative used in the dry powder must
completely dissolve on addition of water to impart the
preservation action.
Sources of this microbial contamination may include air
and water, manufacturing equipment, manufacturing per-
sonnel and/or the consumer [5]. Bacterial contamination
of products through consumer use, has resulted in pres-
ence of mixed and harmful microbial flora in the product
[6].
Major studies on antimalarial formulations are limited to
the active ingredients without mention of the preserva-
tives when studied in syrups and dry powders. In view of
the biological role that this excipient plays towards the
maintenance of the preparation and the recovery of the
patient, there is a dire need for greater attention and
awareness directed towards the importance of preserva-
tion in paediatric formulations.
Several chemical preservative agents exist and have been
widely employed in the cosmetic, food and pharmaceuti-
cal industries [5]. For oral use, the choices of the preserv-
atives are limited. These include benzoic acid (BA)
C6H5COOH and sorbic acid (SA) C5H7COOH, which are
generally effective to control mould and yeast growth, and
the parahydroxybenzoic acid esters: methylparaben (MP)
C6H4(OH)COOCH3  and propylparaben (PP)
C6H4(OH)COOC3H7, which are most commonly used to
control bacterial growth due to their broad antimicrobial
spectrum with good stability and non-volatility [7]. MP
and PP are usually used in combination as they possess a
synergistic activity when used together. However, overuse
of preservatives may cause allergic reactions hence, they
should be shown not to be cytotoxic or sensitizing [8,9].
Recently, the artemisinin-derivative drugs have become a
major target for counterfeiters. Fake and substandard ver-
sions of original brands have previously been reported in
Southeast Asia [10,11] and now in Africa [12]. The sub-
standard copies were present in all dosage forms but most
especially in the tablets and dry powders. In the latter,
quality analysis should also be performed on the preserv-
atives. No report has been published on efficacy of pre-
servatives in artemisinin-like antimalarial drugs.
Thus, the aim of this study was (1) to identify the com-
monly used antimicrobial agents in the artemisinin-con-
taining dry suspensions on the market, (2) study the
dissolution profiles of these preservatives after reconsti-
tuting in water, (3) evaluate the activity of the preserva-
tives by performing the preservative efficacy test (PET) on
the wet suspension and (4) describe some simple analyti-
cal procedures for these analytes in dry powders. The dif-
ferent high performance liquid chromatography (HPLC)
methods used were validated for each analyte.
Methods
Materials and reagents
Potassium dihydrogenphosphate and sodium hydroxide
(both Ph. Eur. grade) were obtained from Merck (Darm-
stadt, Germany) and HPLC grade methanol and ace-
tonitrile were supplied by Fisher Scientific (Leicestershire,
UK). Glacial acetic acid was obtained from JT Baker
(Deventer, The Netherlands) while ammonia (pro ana-
lysi) was supplied by Merck (Darmstadt, Germany).Malaria Journal 2007, 6:12 http://www.malariajournal.com/content/6/1/12
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Methylparaben and propylparaben were obtained from
Federa (Brussels, Belgium), while benzoic acid (pro ana-
lysi) was supplied by Merck (Darmstadt, Germany).
Sorbic acid was bought from Certa (Braine l'Alleud, Bel-
gium). De-ionized milli-Q water was used throughout the
experiment.
Thin layer chromatography (TLC) for the identification of 
preservatives
Of the seven dry suspensions, only the Artenam® and Arte-
siane® samples indicated the type of preservative(s) used
on the package insert. From the literature, the commonly
used preservatives in oral aqueous pharmaceuticals were
retrieved and used to identify the preservatives in the
other samples. The TLC procedure described in the Ph.
Eur. IV for the identification of parabens was initially
tested to separate the four preservatives.
Ca. 100 mg of each of the reference preservative powder
was weighed in separate 100-ml flasks and dissolved to
the mark with methanol. The stationary phase was 10 cm
× 20 cm RP-18 F254S silica gel plates from Merck (Darm-
stadt, Germany). The initial eluent was composed of 70
volumes of methanol, 30 volumes of water and 1 volume
of glacial acetic acid. Several other compositions were
tested to efficiently separate the four components on a
single plate (see Table 1). Five µl of each standard solution
was manually spotted using a glass capillary pipette at 2
cm spot distance. The plates were then developed in
Camag® TLC tanks presaturated with mobile phase. Devel-
opment time was dependent on eluent composition, but
± 30 min was sufficient for most. The plates were allowed
to dry in a well ventilated room. Visualization was on UV
at 254 nm with a Camag® Universal UV Lamp (Muttenz,
Switzerland).
UV spectrophotometry
To identify the preservatives in the other suspensions,
methanol was added to each powder bottle, mixed and
centrifuged at 3,000 rpm (g  = 1,512) for 15 min. The
supernatant was collected and appropriate dilutions were
made in methanol. Spectra acquisition of the samples was
done against a standard solution on a Uvikon 860 spec-
trophotometer (Kontron Instruments, Massachusetts,
USA) connected to a Plotter 800 Integrator (Kontron
Instruments, Massachussetts, USA). Pure methanol was
used as the blank.
HPLC instrumentation
The chromatographic system for the preservatives (MP,
PP, BA and SA) consisted of a Merck-Hitachi L-6000
pump, a Perkin-Elmer LC 90 UV spectrophotometric
detector connected to a Merck-Hitachi D-2500 Chromato-
Integrator. The stationary phase in each case was a
reversed-phase Nucleosil® 120-4 C18 column, 125 mm
long by 4 mm (i.d) and 5 µm particle size from Macherey-
Nagel (Düren, Germany) except for sorbic acid where a
Lichrospher®250 × 4 mm, 5 µm particle size column from
Merck(Darmstadt, Germany)was used. The eluent for the
parabens consisted of an acetonitrile : KH2PO4(0.05 M,
pH 5.0) buffer (300:700, v/v) mixture. The mobile phase
of sorbic acid was composed of a mixture of acetonitrile :
water : KH2PO4(0.05 M, pH5.0) buffer,(100:690:240, v/v/
v)and benzoic acid was separated using acetonitrile
:KH2PO4(0.05 M, pH 5.0) buffer(100:900, v/v) mixture.
Detection of MP and PP was achieved on UV at 254 nm,
290 nm for sorbic acid and 226 nm for benzoic acid. All
analyses were done isocratically at a flow rate of 1.0 ml/
min and 20 µl of each sample was injected. In all experi-
ments, the buffer was adjusted to there quired pH with
sodium hydroxide and filtered using a 0.45 µm pore size
membrane filter before use.
Standard solutions preparation
A bulk powder mixture comprising of ca. 0.08% MP and
0.02% PP was prepared and from this mixture about 50
mg was accurately weighed in a 50-ml flask. This was com-
pletely dissolved to the mark with pure methanol. The
solution was then diluted (100x) with the same solvent
for analysis. Sorbic acid standard solution was prepared
by weighing ca. 160 mg of it and dissolving in 50 ml
methanol. Appropriate dilutions were then made, first
10x in methanol : water (4 : 1, v/v) mixture and then 2.5x
with the mobile phase for injection. Benzoic acid standard
was prepared by accurately weighing 60 mg of it in a 50-
ml volumetric flask and dissolving to the mark with a
Table 1: Mobile phase compositions for the separation of preservatives by TLC (detected at 254 nm)
Retardation factor (RF)
Mobile phase (v/v/v) Methylparaben Propylparaben Sorbic acid Benzoic acid
CH3OH/H2O (80/20) 0.70 0.57 0.68 0.69 (Faint spot)
CH3OH/H2O/CH3COOH (70/30/1) 0.47 0.28 0.47 0.50 (Faint spot)
CH3OH/H2O/CH3COOH (80/20/1) 0.75 0.67 0.75 0.75
CH3OH/H2O/CH3COOH (80/20/3) 0.57 0.48 0.64 0.64 (Faint spot)
CH3OH/H2O/NH3 (80/20/1) 0.80 0.70 0.87 Highly faint spot
CH3CN/H2O/CH3COOH (95/5/1) 0.88 0.81 0.84 Highly faint spotMalaria Journal 2007, 6:12 http://www.malariajournal.com/content/6/1/12
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methanol : water (900 : 100, v/v) mixture. From this a 20x
dilution was made with a methanol : KH2PO4 (0.05 M,
pH 5.0) buffer (50:50 v/v).
Preservative content in dry powders
All powders analysed in this study were anonymously
obtained from pharmacies within Nairobi in Kenya (East
Africa). An Artenam® semi-industrial batch dry powder
suspension containing artemether (180 mg/60 ml) was
added to the study. From each product the following were
noted: type and dose of active ingredient and type of pre-
servative (if indicated) and registration status. All analyses
were performed before the expiry dates of the product.
Powder in each bottle was shaken to free the particles. For
the dihydroartemisinin dry powders, exactly 200 ml of
methanol : water (80 : 20, v/v) mixture was added to
reduce the influence of the matrix and powder volume on
the analysis. This solvent mixture was necessary to dis-
solve both the active and the preservative in order to use
the content of the same bottle for both analyses. For the
artemether dry powders, exactly 200 ml of pure methanol
was added to the content. All the bottles were then thor-
oughly mixed and left on the shaking apparatus for at
least 1 hour followed by ultrasonication for 15 min. Part
of the suspension was transferred to 5-ml Falcon®tubes
and centrifuged at 3,000 rpm (g = 1,512) for 15 min.
Dissolution of preservatives in the reconstituted 
suspensions
The instructions described by each manufacturer were fol-
lowed for reconstitution. Milli-Q water was added to each
powder, well mixed till complete dispersion and part of
the suspension was taken to determine its pH. From the
rest a suitable volume was transferred to Falcon® tubes and
centrifuged at 3,000 rpm (g = 1,512) for 15 min. For the
more viscous suspensions, the centrifugation step was
repeated on the supernatant. The density of the superna-
tant was measured and subsequent volumes were deter-
mined by sample weighing. Appropriate dilutions of the
supernatant were done for HPLC analysis at the following
time points: immediately after reconstitution (t0), 6
hours, 24 hours, 4 days and 7 days respectively; the maxi-
mum period necessary for a complete treatment of severe
malaria and during which the suspension is supposed to
be stable.
Preservative efficacy test
The method described in the European Pharmacopoeia IV
5.1.3 'Efficacy of Antimicrobial Preservation' was used [3].
The test consisted of challenging the reconstituted suspen-
sions in their final containers with a prescribed inoculum
of the following micro-organisms: Pseudomonas aeruginosa
ATCC 9027, Staphylococcus aureus ATCC 6538, Escherichia
coli ATCC 8739, Candida albicans ATCC 10231, Zygosac-
charomyces rouxii NCYC 381 and Aspergillus niger ATCC
16404. The inoculated preparations were then stored at
ambient temperature and samples were withdrawn at
specified time intervals and the remaining micro-organ-
isms counted.
Results
Preservative identification
TLC experiments were done using the standard solutions
of methylparaben, propylparaben, benzoic acid and
sorbic acid to rapidly check the possibility of separating
and identifying all four preservatives on a single plate. Vis-
ualization was done at 254 nm. The spots of MP, PP and
SA were clearly visible on the plates. Only benzoic acid
showed faint spots. Methylparaben and propylparaben
were well separated from each other but there was more or
less a constant RF(retardation factor) value for methylpa-
raben and sorbic acid when different solvent systems were
tried (Table 1). Changing eluent compositions did not
effectively resolve all four analytes. A system that came
close to a good separation was methanol : water : ammo-
nia (80 : 10 : 1, v/v/v) with RFvalues of 0.80, 0.70, 0.87 for
MP, PP and SA respectively (Figure 1). The manufacturers
and origin of the different powders are presented in Table
2. UV spectra revealed the presence of four different pre-
servative in the dry powders; MP and PP in Artesiane®,
Gvither® and Alaxin®, benzoic acid in Artexin® and San-
tecxin® and sorbic acid in Artenam® respectively. Cotecxin®
did not exhibit any clear UV spectrum however, a personal
correspondence with the manufacturers stated chlorbuta-
nol as the preservative used. For quantification, spectro-
photometry was not a good method since preservatives
that exist in combination such as the parabens will absorb
at the same wavelength [13]. In addition, an excipient that
can interfere with the analyte cannot be separated on UV
thus, HPLC-UV was used in subsequent experiments.
Preservatives content and dissolution
In the dry powders, 0.076% MP and 0.020% PP were
found in Artesiane®, 0.088% MP and 0.011% PP in
Alaxin® while 0.178% MP and 0.057% PP were found in
Gvither® respectively. 0.268% sorbic acid was present in
Artenam®  while Santecxin®  contained 0.031% benzoic
acid and Artexin® 0.148% benzoic acid (Table 2). The nor-
mal aqua concentrations of parabens used in pharmaceu-
tical products are 0.08% MP and 0.02% PP (when used in
combination), 0.10% BA and 0.20% SA respectively [14].
However, in a powder mixture with a complex matrix
these amounts may vary.
After reconstitution (addition of water) only the benzoic
acid (Santecxin® and Artexin®) and the sorbic acid (Arte-
nam®) containing products completely and immediately
dissolved their preservatives (Figures 2 and 3) and the lev-
els remained unchanged during the 7 days study period.Malaria Journal 2007, 6:12 http://www.malariajournal.com/content/6/1/12
Page 5 of 8
(page number not for citation purposes)
None of the parabens immediately dissolved and the rate
of dissolution differed between MP and PP in the same
suspension and within different suspensions (Figures 4
and 5). Artesiane® reached the 90% dissolution rate only
after 24 hrs in PP and this remained stable for up to day 7.
On the other hand, the total level of MP dissolved in the
same sample did not exceed 74%. At t0 the amounts of
preservative dissolved were 64.9% MP and 85.3% PP for
Artesiane®, 28.8% MP and 30.1% PP for Gvither®, and
78.8% MP and 45.3% PP for Alaxin®respectively. Gvither®
possessed the most slowly dissolving parabens and only a
maximum of 45.4% MP and 79.2% PP were present after
7 days (Figures 4 and 5). All the drug formulations were
registered at the Drug Regulatory Agency of Kenya.
Efficacy of antimicrobial preservation
A preservative efficacy test gives an indication of the anti-
microbial activity of a preservative in a preparation. The
preservative properties of the preparation were considered
adequate if, in the conditions of the test, there was a sig-
nificant fall or no increase in the number of micro-organ-
isms at the conditions tested. In the tested wet
suspensions only two samples, Artenam® and Gvither®
met the specific requirements of the European Pharmaco-
poeia of PET in the killing of the micro-organisms. The
other five products failed the test (Table 3). In the latter,
different pathogen strains were observed with Santecxin®
and Cotecxin® retaining the most species of microbes (≥ 4
out of 6 tested pathogens remained positive). Alaxin® and
Artexin® were positive for two microbial species while
Artesiane® was positive for one. In all samples, the fungus
Aspergillus niger was the most positively tested microbe.
pH of reconstituted suspensions
Since a suitable pH is inevitable for the proper function-
ing of the preservatives, the pH of each reconstituted sus-
pension was measured. The pH ranged from 4.50 to 5.90
in all wet suspensions (Table 3). The pH of two suspen-
sions (Santecxin® pH 5.55 and Artexin® pH 5.90) exceeded
by far the pKa of their preservative, benzoicacid (pKa4.20).
The pH of Artenam® wet suspension was 4.50(pKa sorbic
acid 4.76) while the pH of the Artesiane®, Alaxin® and
Gvither® formulations were respectively 5.43, 4.40 and
4.30(pKa parabens 8.4).
Discussion
Artemisinin and its semi-synthetic derivatives are cur-
rently the most effective antimalarial compounds on the
market. The dry suspension preparations of these drugs
are of particular importance since they are specifically
made for children (though the dose can also be adapted
to an adult patient). This is a very vulnerable age group
and more precaution is, therefore, necessary in formulat-
ing their medicines. In all such preparations a suitable
preservative has to be added. In the tropics, where temper-
atures tend to be high in addition to high relative humid-
ity, microbial contamination of the reconstituted
suspension (and possible patient co-infection) can be
common. In fact, in view of the possibility of using con-
taminated drinking water, most of the drug manufacturers
advised that only boiled and cooled water should be used
to reconstitute the suspension.
Regulatory law requires that preservatives must be listed
by their common or usual names on ingredient labels of
all drugs that contain them. Most manufacturers failed to
indicate the type of preservative and the composition of
other excipients in the formulation. This practice shades
vital drug information, which is necessary for the patient,
TLC plate showing the separation of preservatives (1 =  methylparaben, 2 = propylparaben, 3 = benzoic acid, 4 =  sorbic acid) using a solvent mixture of methanol : water :  ammonia (80 : 20 : 1, v/v/v) Figure 1
TLC plate showing the separation of preservatives (1 = 
methylparaben, 2 = propylparaben, 3 = benzoic acid, 4 = 
sorbic acid) using a solvent mixture of methanol : water : 
ammonia (80 : 20 : 1, v/v/v)
1
2
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medical practitioners, researchers and the regulatory
authorities.
It was not possible to use TLC alone to identify the pre-
servatives present in the preparations due to the difficulty
in separating methylparaben from sorbic acid as their
RFvalues were nearly always the same (Table 1). With nor-
mal phase plates similar separation problems were
encountered. The UV lamp used in spot visualization was
set at two standard wavelengths only, 254 nm and 366 nm
hence, the faint spots observed with benzoic acid would
probably be due to its low absorption at 254 nm (λmax BA
= 226 nm).
It is unclear what the recommended concentration of a
preservative in a dry suspension is supposed to be. Noth-
ing is mentioned in the United States Pharmacopoeia
(USP) or the European Pharmacopoeia (Ph. Eur.) on the
actual limits necessary hence, this leaves room for the for-
mulators to employ different amounts of the same pre-
servative; sometimes to detriment of the patient. This
disparity in concentration is clearly observed in all the
products (Table 2). The total amount of a preservative
present in a dry powder is required to be available in the
wet suspension. None of the paraben formulations met
this criterion. In some drugs, values containing as low as
30% only of preservative were released after reconstitu-
tion. This leaves the drug susceptible to contamination.
The ICH recommends that content limits of the preserva-
tive of between 90–110% at release should be acceptable.
However, Ofner III et al [15] suggested that degradation of
the preservative is acceptable as long as sufficient preserv-
ative is present to maintain effectiveness. To accomplish
this, the use of the right type and quality of the preserva-
tive is primordial. For instance, esters of parahydroxyben-
zoic acids are slightly soluble in water and there is the
danger that in the dry powders they may not dissolve fast
enough after adding water. For such preparations, their
acid salts such as sodium alkylparabens are preferred.
Because the parabens took several days to reach their end
concentration in the wet suspension, this may suggest that
only the acid form of the preservative was used. Secondly,
Dissolution profile of sorbic acid (SA) Figure 3
Dissolution profile of sorbic acid (SA)
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Table 2: Concentration of preservative(s) in dry suspensions after reconstitution
Product/Manufacturer Active ingredient/Dose Preservative(s) identified % preservative found Normal value in 
H2O+ (%)
Artenam®* Arenco, Belgium Artemether 180 mg/60 ml Sorbic acid 0.27 0.20
Gvither® GVS Labs, India Artemether 300 mg/100 ml Methylparaben 0.18 0.08
Propylparaben 0.06 0.02
Artesiane® Dafra, Belgium Artemether 300 mg/100 ml Methylparaben 0.08 0.08
Propylparaben 0.02 0.02
Alaxin® GVS Labs, India Dihydroartemisinin 160 mg/80 ml Methylparaben 0.09 0.08
Propylparaben 0.01 0.02
Artexin® Sphinx Pharma, Kenya Dihydroartemisinin 160 mg/80 ml Benzoic acid 0.15 0.10
Santecxin® Shsj, China Dihydroartemisinin 160 mg/80 ml Benzoic acid 0.03 0.10
Cotecxin®, Jiaxing Nanhu Pharma, China Dihydroartemisinin 160 mg/80 ml Chlorbutanol? Not tested 0.50
* Semi-industrial batch, + Source: Martindale (The Complete Drug Reference) 1999.
Dissolution profiles of benzoic acid (BA) Figure 2
Dissolution profiles of benzoic acid (BA)
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100% of the dissolved preservative could not be retrieved
due to the possibility of preservative adsorption on the
solids and/or complex formation on the macromolecules
in the suspension such as suspending agents [16]. Studies
have shown that parabens adsorb to the surface of the
container-closure system especially plastic containers. The
latter are commonly employed in paediatric formulations
[17]. All products used this packaging except the Artexin®
preparation which employed a brown bottle packaging.
Due to the possibility of the interactions mentioned
above, only the free fraction of the preservative can be
active. Thus, the formulator has to be able to strike a bal-
ance between a level high enough to pass the preservative
efficacy test and low enough to prevent adverse reactions.
The efficacy of a preservative depends not only on its con-
centration but also on the pH of the suspension. For pre-
servatives that are carboxylic acids, only the un-ionized
species is microbicidal. The pKa  of such preservatives
therefore determines the pH range in which the preserva-
tive is effective. The antimicrobial activity of the parabens,
benzoic acid, sorbic acid and others certainly decreases as
pH increases past their respective pKa [5]. It is, therefore,
possible that though Artexin® contained an high amount
of benzoic acid (0.148%), its antimicrobial efficacy was
not adequate since the pH of the reconstituted suspension
of 5.90 exceeded the pKa of BA. This high pH dissociates
the acid into the salt form leaving only a small undissoci-
ated fraction. On the other hand, Santecxin® contained a
very low amount of benzoic acid (only 0.031%) which
probably was insufficient to impart the preservative's
activity. The pH of all paraben formulations (Artesiane®,
Gvither® and Alaxin®) was lower than their pKa ; hence
inadequate antimicrobial efficiency could not be due to
chemical dissociation. Though the Gvither® sample con-
tained the least dissolved parabens, its preservative effi-
cacy test passed the requirements. This is probably due to
the very high amounts of these substances present in the
original formulation (0.178% MP and 0.057% PP respec-
tively).
Though there are not many antimalarial dry powders on
the market, a more prospective and large scale study
involving samples collected in different endemic regions
Table 3: Efficacy of antimicrobial preservation of the artemisinin-derivative reconstituted suspensions
pH wet suspension Preservative P. aeruginosa S. aureus E. coli C. albicans Z. rouxii A. niger Ph. Eur. requirements
Artenam® 4.50 Sorbic acid - - - - - - Conforms
Gvither® 4.30 MP/PP - - - - - - Conforms
Artesiane® 5.43 MP/PP - - - - - + Does not conform
Alaxin® 4.40 MP/PP - + - - - + Does not conform
Artexin® 5.90 Benzoic acid + - + - - - Does not conform
Santecxin® 5.55 Benzoic acid + - + + + + Does not conform
Cotecxin® not tested Chlorbutanol? - - + + + + Does not conform
+ = positive for the tested microorganisms, - = negative for the tested microorganisms
MP = methylparaben, PP = propylparaben
Dissolution profiles of methylparaben (MP) Figure 4
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Dissolution profiles of propylparaben (PP)
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is necessary to ascertain the impact of preservation on the
products. This initial study portrays the importance of
preservation in aqueous antimalarial compounds.
Conclusion
The high number of failures of the artemisinin-derivatives
dry suspensions with respect to their antimicrobial preser-
vation suggests that the surveillance of the marketed drugs
may be ineffective in Kenya.
Effective preservation of paediatric formulations devel-
oped in multi-dose containers is necessary, as it contrib-
utes to the microbiological stability of the suspension as
well as safeguard patient infection due to the formulation.
Especially for children, paediatric medicines requiring a
water phase need strict control on the content and efficacy
of both the active ingredient as well as the preservative
prior to registration. Above all, monitoring should con-
tinue after the drugs are on the market.
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